Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Verve Therapeutics Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) July 01, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors June 28, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 31, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Leadership Update May 31, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Participate in Upcoming Investor Conferences May 30, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results May 08, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 May 07, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Updates on its PCSK9 Program April 02, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 28, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 01, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement December 01, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement November 28, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement November 28, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia November 12, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results November 07, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 October 31, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia October 23, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023 September 26, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference September 21, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer September 18, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results August 10, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference August 03, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference June 01, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day May 23, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results May 15, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference May 09, 2023 From Verve Therapeutics Via GlobeNewswire Tickers VERV Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.